The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Open accessAbstract
BACKGROUND: Nivolumab plus ipilimumab showed promising efficacy for the treatment of non-small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potential biomarker of benefit. In this part of an open-label, multipart, phase 3 trial, we examined progression-free survival with nivolumab plus ipilimumab versus chemotherapy among patients with a high tumor mutational burden (≥10 mutations per megabase). METHODS: We enrolled patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy. Those with a level of tumor programmed death ligand 1 (PD-L1) expression of at least 1% were randomly assigned, in a 1:1:1 ratio, to receive nivolumab plus ipilimumab, nivolumab monotherapy, or chemotherapy; those with a tumor PD-L1 expression level of less than 1% were randomly assigned, in a 1:1:1 ratio, to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy. Tumor mutational burden was determined by the FoundationOne CDx assay. RESULTS: Progression-free survival among patients with a high tumor mutational burden was significantly longer with nivolumab plus ipilimumab than with chemotherapy. The 1-year progression-free survival rate was 42.6% with nivolumab plus ipilimumab versus 13.2% with chemotherapy, and the median progression-free survival was 7.2 months (95% confidence interval [CI], 5.5 to 13.2) versus 5.5 months (95% CI, 4.4 to 5.8) (hazard ratio for disease progression or death, 0.58; 97.5% CI, 0.41 to 0.81; P<0.001). The objective response rate was 45.3% with nivolumab plus ipilimumab and 26.9% with chemotherapy. The benefit of nivolumab plus ipilimumab over chemotherapy was broadly consistent within subgroups, including patients with a PD-L1 expression level of at least 1% and those with a level of less than 1%. The rate of grade 3 or 4 treatment-related adverse events was 31.2% with nivolumab plus ipilimumab and 36.1% with chemotherapy. ical; CheckMate 227 ClinicalTrials.gov number, NCT02477826 .). CONCLUSIONS: Progression-free survival was significantly longer with first-line nivolumab plus ipilimumab than with chemotherapy among patients with NSCLC and a high tumor mutational burden, irrespective of PD-L1 expression level. The results validate the benefit of nivolumab plus ipilimumab in NSCLC and the role of tumor mutational burden as a biomarker for patient selection. (Funded by Bristol-Myers Squibb and Ono Pharmaceut
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Currently, limited biomarkers, such as PD-L1 expression (88) and tumor mutation load (TMB) (89–91), are clinically used to predict the immunotherapy benefit.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citationGenetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,002
Patkar, S., Chen, A., Basnet, A., Bixby, A., Rajendran, R., Chernet, R., Faso, S., Kumar, P. A., Desai, D., El-Zammar, O., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00765-w · Cited by 41
Shen, C., Zhang, Z., Tian, Y., Li, F., Zhou, L., Jiang, W., Yang, L., Zhang, B., Wang, L., & Zhang, Y. (2021) · BMC Medicine · doi:10.1186/s12916-021-02161-8 · Cited by 39
Ancel, J., Dormoy, V., Nawrocki‐Raby, B., Dalstein, V., Durlach, A., Dewolf, M., Gilles, C., Polette, M., & Deslée, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1171649 · Cited by 36
CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer
Lau, A. P. Y., Binstock, S. S. K., & Thu, K. L. (2023) · Cancers · doi:10.3390/cancers15215229 · Cited by 39
Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis
Yamada, K., Takeuchi, M., Fukumoto, T., Suzuki, M., Kato, A., Mizuki, Y., Yamada, N., Kaneko, T., Mizuki, N., & Horita, N. (2024) · Scientific Reports · doi:10.1038/s41598-024-55675-5 · Cited by 38
Is earlier better for melanoma checkpoint blockade?
Robert, C. (2018) · Nature Medicine · doi:10.1038/s41591-018-0250-0 · Cited by 37
Park, W., & Lopes, G. D. L., Jr. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.12.003 · Cited by 37
Complete and Prolonged Response to Immune Checkpoint Blockade in POLE-Mutated Colorectal Cancer
Silberman, R., Steiner, D. F., Lo, A. A., Gomez, A. J., Zehnder, J. L., Chu, G., & Suarez, C. J. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00214 · Cited by 37
Jang, H.-J., Lee, H., Ramos, D., Park, I. K., Kang, C. H., Burt, B. M., & Kim, Y. T. (2019) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2019.10.123 · Cited by 35
Bozorgmehr, F., Hommertgen, A., Krisam, J., Lasitschka, F., Kuon, J., Maenz, M., Huber, P. E., König, L., Kieser, M., Debus, J., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6205-0 · Cited by 36
Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018
Hu, Z., Li, M., Chen, Z., Zhan, C., Lin, Z., & Wang, Q. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.10.17 · Cited by 36
Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge
Yang, Y., Yu, Y., & Lü, S. (2020) · Science China Life Sciences · doi:10.1007/s11427-019-1622-5 · Cited by 37
Bcl6 Preserves the Suppressive Function of Regulatory T Cells During Tumorigenesis
Li, Y., Wang, Z., Lin, H., Wang, L., Chen, X., Liu, Q., Zuo, Q., Hu, J., Wang, H., Guo, J., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00806 · Cited by 32
Xie, X., Li, Y., Zhao, D., Fang, C., He, D., Yang, Q., Yang, L., Chen, R., Tan, Q., & Zhang, J. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102261 · Cited by 36
DNA Repair and Signaling in Immune-Related Cancer Therapy
Kakoti, S., Sato, H., Laskar, S. S., Yasuhara, T., & Shibata, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00205 · Cited by 36
Gobbini, É., Swalduz, A., Levra, M. G., Ortiz‐Cuaran, S., Toffart, A., Pérol, M., Moro‐Sibilot, D., & Saintigny, P. (2020) · Cancers · doi:10.3390/cancers12113112 · Cited by 36
Is immunotherapy in the future of therapeutic management of sarcomas?
Clemente, O., Ottaiano, A., Lorenzo, G. D., Bracigliano, A., Lamia, S., Cannella, L., Pizzolorusso, A., Marzo, M. D., Santorsola, M., Chiara, A. D., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02829-y · Cited by 38
Li, L., Lu, G., Liu, Y., Gong, L., Zheng, X. Y., Zheng, H., Gu, W., & Yang, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.658690 · Cited by 39
Criscitiello, C., Guerini‐Rocco, E., Viale, G., Fumagalli, C., Sajjadi, E., Venetis, K., Piciotti, R., Invernizzi, M., Malapelle, U., & Fusco, N. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210706144112 · Cited by 36
Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
Shen, P., Han, L., Ba, X., Qin, K., & Tu, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.678409 · Cited by 36
Mondelo‐Macía, P., García, J., León‐Mateos, L., Anido, U., Aguín, S., Abdulkader, I., Sánchez‐Ares, M., Abalo, A., Rodríguez‐Casanova, A., Díaz‐Lagares, Á., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13094 · Cited by 36
Burcher, K. M., Lantz, J. W., Gavrila, E., Abreu, A., Burcher, J. T., Faucheux, A. T., Xie, A., Jackson, C. W., Song, A. H., Hughes, R. T., et al. (2021) · Cancers · doi:10.3390/cancers13225733 · Cited by 40
Zhao, C., Jiang, T., Ju, J. H., Zhang, S., Tao, J., Fu, Y. S., LoCoco, J. S., Dockter, J., Pawlowski, T. L., & Bilke, S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.21.349100 · Cited by 35
Self-citationBorghaei, H., Ciuleanu, T., Lee, J.-S., Płużański, A., Caro, R. B., Gutierrez, M. E., Ohe, Y., Nishio, M., Goldman, J. W., Ready, N., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.11.006 · Cited by 35
Self-citationVardarli, I., Tan, S., Brandenburg, T., Weidemann, F., Görges, R., Herrmann, K., & Führer, D. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad670 · Cited by 40
Predictive biomarkers for immunotherapy response in extensive-stage SCLC
Zhu, L., & Qin, J. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05544-x · Cited by 38
Laguna, J. C., Tagliamento, M., Lambertini, M., Hiznay, J. M., & Mezquita, L. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432488 · Cited by 40
Cancer Immunotherapy: The Dawn of Antibody Cocktails
Marrocco, I., Romaniello, D., & Yarden, Y. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8958-4_2 · Cited by 36
Ackermann, C. J., Reck, M., Paz-Ares, L. G., Barlési, F., & Califano, R. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.06.007 · Cited by 35
Self-citationHuang, D., Zhang, F., Tao, H., Zhang, S., Ma, J., Wang, J., Liu, Z., Cui, P., Chen, S., Huang, Z., et al. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00703-3 · Cited by 35
Advances in theranostic biomarkers for tumor immunotherapy
Bellesœur, A., Torossian, N., Amigorena, S., & Romano, E. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.02.005 · Cited by 34
Tsuruoka, K., Wakabayashi, S., Morihara, H., Matsunaga, N., Fujisaka, Y., Goto, I., Imagawa, A., & Asahi, M. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.04.033 · Cited by 35
In, G. K., Poorman, K. A., Saul, M. E., O'Day, S. J., Farma, J. M., Olszanski, A. J., Gordon, M. S., Thomas, J. S., Eisenberg, B. L., Flaherty, L. E., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27686 · Cited by 38
Wu, B. Y., & Lü, S. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-19-605 · Cited by 35
Ren, C., Mai, Z.-J., Jin, Y., He, M.-M., Wang, Z., Luo, H., Zhang, D., Wu, C.-Y., Wang, F., & Xu, R. (2020) · PubMed Central · Cited by 35
Xie, F., Bai, Y., Yang, X., Long, J., Mao, J., Lin, J., Wang, D., Song, Y., Xun, Z., Huang, H., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107135 · Cited by 37
Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs
Drakes, M. L., Czerlanis, C. M., & Stiff, P. J. (2020) · Cancers · doi:10.3390/cancers12113301 · Cited by 34
Ramos‐Paradas, J., Hernández-Prieto, S., Lora, D., Sanchez, E., Rosado, A., Caniego-Casas, T., Carrizo, N., Enguita, A. B., Muñoz-Jimenez, M. T., Rodriguez, B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001904 · Cited by 35
Self-citationPerioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
Soh, J., Hamada, A., Fujino, T., & Mitsudomi, T. (2021) · Cancers · doi:10.3390/cancers13164035 · Cited by 35
Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples
Tomlins, S. A., Hovelson, D. H., Suga, J. M., Anderson, D. M., Koh, H. A., Dees, E. C., McNulty, B., Burkard, M. E., Guarino, M. J., Khatri, J., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00472 · Cited by 36
Huang, B.-J., Shi, H., Gong, X.-H., Yu, J., Xiao, C., Zhou, B., Liang, Z.-B., & Li, X. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-610 · Cited by 31
Janoštiak, R., Torres-Sanchez, A., Posas, F., & de Nadal, E. (2022) · Cancers · doi:10.3390/cancers14051265 · Cited by 40
Smolle, E., Leithner, K., & Olschewski, H. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13246 · Cited by 36
Deep learning in digital pathology for personalized treatment plans of cancer patients
Wen, Z., Wang, S., Yang, D. M., Xie, Y., Chen, M., Bishop, J., & Xiao, G. (2023) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2023.02.003 · Cited by 34
Ma, Y., Ma, X., Wang, J., Wu, S., Wang, J., & Cao, B. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02695-y · Cited by 34
Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
van de Haar, J., Mankor, J. M., Hummelink, K., Monkhorst, K., Smit, E. F., Wessels, L. F. A., Cuppen, E. P. J. G., Aerts, J. G. J. V., & Voest, E. E. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-4027 · Cited by 40
Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer—where are we?
Evans, M., O’Sullivan, B., Smith, M. R., & Tanière, P. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.06.09 · Cited by 35
Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges
Regzedmaa, O., Zhang, H., Liu, H., & Chen, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s204577 · Cited by 34
Heeke, S., Benzaquen, J., Long-Mira, É., Audelan, B., Lespinet‐Fabre, V., Bordone, O., Lalvée, S., Zahaf, K., Poudenx, M., Humbert, O., et al. (2019) · Cancers · doi:10.3390/cancers11091271 · Cited by 35
Therapeutic Development of Immune Checkpoint Inhibitors
Wang, J., Yang, T., & Xu, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_23 · Cited by 34
Heterogeneity of MSI-H gastric cancer identifies a subtype with worse survival
Yang, Y., Shi, Z. Q., Bai, R., & Hu, W. (2020) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2019-106609 · Cited by 34
Efficacy of Immune Checkpoint Inhibitors and Age in Cancer Patients
Huang, X., Gao, P., Song, Y., Sun, J., Chen, X., Zhao, J., & Wang, Z. (2020) · Immunotherapy · doi:10.2217/imt-2019-0124 · Cited by 36
Lamberti, G., Andrini, E., Sisi, M., Federico, A. D., & Ricciuti, B. (2020) · Future Oncology · doi:10.2217/fon-2020-0215 · Cited by 36
Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer
Liu, W., Zhang, L., Xiu, Z., Guo, J., Wang, L., Zhou, Y., Jiao, Y., Sun, M., & Cai, J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s255491 · Cited by 34
Walter, W., Pfarr, N., Meggendorfer, M., Jost, P. J., Haferlach, T., & Weichert, W. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.10.015 · Cited by 35
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
Hu‐Lieskovan, S., Bhaumik, S., Dhodapkar, K. M., Grivel, J., Gupta, S. V., Hanks, B. A., Janetzki, S., Kleen, T. O., Koguchi, Y., Lund, A. W., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000705 · Cited by 35
Giustini, N., & Bazhenova, L. A. (2021) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s235102 · Cited by 36
Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice
Roberto, M., Botticelli, A., Panebianco, M., Aschelter, A. M., Gelibter, A. J., Ciccarese, C., Minelli, M., Nuti, M., Santini, D., Laghi, A., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.657639 · Cited by 36
Chi, A., He, X., Hou, L., Nguyen, N. P., Zhu, G., Cameron, R. B., & Lee, J. M. (2021) · Cancers · doi:10.3390/cancers13122924 · Cited by 36
Self-citationMa, L., Diao, B., Huang, Z., Wang, B., Yu, J., & Meng, X. (2021) · 癌症：英文版 · doi:10.1002/cac2.12229 · Cited by 33
Biomarkers related to immune checkpoint inhibitors therapy
Li, N., Hou, X., Huang, S., Tai, R., Lei, L., Li, S., Abuliz, A., Wang, G., & Yang, S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112470 · Cited by 34
John, T., Sakai, H., Ikeda, S., Cheng, Y., Kasahara, K., Sato, Y., Nakahara, Y., Takeda, M., Kaneda, H., Zhang, H., et al. (2022) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02120-0 · Cited by 33
Liu, Y., Xu, Y., Cheng, X., Lin, Y., Jiang, S., Yu, H., Zhang, Z., Lu, L., & Zhang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.862084 · Cited by 36
Neoantigen-directed therapeutics in the clinic: where are we?
Lybaert, L., Thielemans, K., Feldman, S. A., van der Burg, S. H., Bogaert, C., & Ott, P. A. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.02.004 · Cited by 35
An integrative pan-cancer analysis of COPB1 based on data mining
Chen, H., Li, K., Li, Y., Xie, P., He, J., & Zhang, H. (2020) · Cancer Biomarkers · doi:10.3233/cbm-200398 · Cited by 33
Nano-immunotherapy for lung cancer
Lu, Y., Zeng, T., Zhang, H., Li, Y., Zhu, X., Liu, H., Sun, B., Ji, C., Li, T., Huang, L., et al. (2023) · Nano TransMed · doi:10.26599/ntm.2023.9130018 · Cited by 33
Jiang, H., & Zhang, Q. (2024) · Oncology Letters · doi:10.3892/ol.2024.14221 · Cited by 34
Jones, N., Xiu, J., Rocconi, R. P., Herzog, T. J., & Winer, I. S. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.11.035 · Cited by 35
Update on emerging biomarkers in lung cancer
Bernicker, E., Allen, T. C., & Cagle, P. T. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.01.46 · Cited by 33
Yang, W., Li, S., & Yang, Q. (2019) · Medicine · doi:10.1097/md.0000000000015731 · Cited by 33
Bevins, N., Sun, S., Gaieb, Z., Thorson, J., & Murray, S. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000613 · Cited by 36
Contribution of Macrophages and T Cells in Skeletal Metastasis
Mendoza‐Reinoso, V., McCauley, L. K., & Fournier, P. G. J. (2020) · Cancers · doi:10.3390/cancers12041014 · Cited by 35
Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC)
Mildner, F., Sopper, S., Amann, A., Pircher, A., Pall, G., Koeck, S., Naismith, E., Wolf, D. G. F., & Gamerith, G. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102948 · Cited by 36
Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver
Kim, S. Y., & Halmos, B. (2020) · Lung Cancer Management · doi:10.2217/lmt-2020-0003 · Cited by 33
Halbert, B. T., & Einstein, D. J. (2020) · Urology · doi:10.1016/j.urology.2020.10.030 · Cited by 32
Nicoś, M., Krawczyk, P. A., Crosetto, N., & Milanowski, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.569202 · Cited by 32
Immunotherapy Use in Patients With Lung Cancer and Comorbidities
von Itzstein, M. S., Gonugunta, A. S., Mayo, H., Minna, J. D., & Gerber, D. E. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000484 · Cited by 33
Immunotherapy for the treatment of colorectal cancer
Lumish, M. A., & Cercek, A. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26357 · Cited by 34
Strategies to overcome resistance to immune checkpoint blockade in lung cancer
Attili, I., Tarantino, P., Passaro, A., Stati, V., Curigliano, G., & de Marinis, F. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.02.035 · Cited by 33
Luo, B., Zhang, Y., Zhang, C., Liu, X., & Shi, C. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.001 · Cited by 33
Choudhury, N. J., Schneider, J. L., Patil, T., Zhu, V. W., Goldman, D. A., Yang, S., Falcon, C. J., Do, A., Nie, Y., Plodkowski, A. J., et al. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100187 · Cited by 33
Passiglia, F., Galvano, A., Gristina, V., Barraco, N., Castiglia, M., Perez, A., Mantia, M. L., Russo, A. D., & Bazan, V. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-52 · Cited by 33
Liberini, V., Mariniello, A., Righi, L., Capozza, M., Delcuratolo, M. D., Terreno, E., Farsad, M., Volante, M., Novello, S., & Deandreis, D. (2021) · Cancers · doi:10.3390/cancers13184543 · Cited by 33
On-Target Side Effects of Targeted Therapeutics of Cancer
Tímár, J., & Uhlyarik, A. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610694 · Cited by 34
Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck
Saada-Bouzid, E., Peyrade, F., & Guigay, J. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000522 · Cited by 35
TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy
Qiu, H., Shao, Z., Wen, X., Jiang, J., Ma, Q., Wang, Y., Huang, L., Ding, X., & Zhang, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.716710 · Cited by 32
The clinical and immune features of CD14 in colorectal cancer identified via large-scale analysis
Chen, D., & Wang, H. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106966 · Cited by 33
Liu, S., Tang, Q.-J., Huang, J., Zhan, M., Zhao, W., Yang, X., Li, Y., Qiu, L., Zhang, F., Lu, L., et al. (2021) · Aging · doi:10.18632/aging.202811 · Cited by 33
Huang, R. S. P., Carbone, D. P., Li, G., Schrock, A. B., Graf, R. P., Zhang, L., Murugesan, K., Ross, J. S., Tolba, K. A., Sands, J. M., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005801 · Cited by 37
Benito, J. M., Restrepo, C., García‐Foncillas, J., & Rallón, N. I. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1270881 · Cited by 36
Somatic mutation of LRP1B is associated with tumor mutational burden in patients with lung cancer
Lan, S., Li, H., Liu, Y., Ma, L., Liu, X., Liu, Y., Yan, S., & Cheng, Y. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.04.025 · Cited by 32
Ho, H., Chou, T., Yang, S.-H., Jiang, J., Chen, W.-S., Chao, Y., & Teng, H. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02942-y · Cited by 31
Circulating biomarkers predictive of tumor response to cancer immunotherapy
Lee, E. Y., & Kulkarni, R. P. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1659728 · Cited by 33
Costantini, A., Kamga, P. T., Duménil, C., Chinet, T., Emile, J., & Leprieur, E. G. (2019) · Cancers · doi:10.3390/cancers11091269 · Cited by 32
Wang, S., Hu, C., Xie, F., & Liu, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s235714 · Cited by 32
D’Costa, N. M., Lowerison, M. R., Raven, P. A., Tan, Z., Roberts, M. E., Shrestha, R., Urban, M. W., Monjarás-Ávila, C. U., Oo, H. Z., Hurtado‐Coll, A., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-1527-y · Cited by 31
Principles of Immunotherapy in Non-Small Cell Lung Cancer
Hsu, M. L., & Naidoo, J. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.009 · Cited by 33
Challenges of PD-L1 testing in non-small cell lung cancer and beyond
Wang, M., Wang, S., Trapani, J. A., & Neeson, P. J. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-2019-itm-010 · Cited by 31
Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer
Duchemann, B., Remón, J., Naigeon, M., Cassard, L., Jouniaux, J.-M., Boselli, L., Grivel, J., Auclin, É., Desnoyer, A., Besse, B., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-839 · Cited by 33
Wu, C., Rao, X., & Lin, W. L. (2020) · Cancer Medicine · doi:10.1002/cam4.3655 · Cited by 32
Metadata
- Authors
- Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., Borghaei, H., Ramalingam, S. S., Brahmer, J., Reck, M., O’Byrne, K. J., Geese, W. J., Green, G., Chang, H., Szustakowski, J., Bhagavatheeswaran, P., Healey, D., Fu, Y., Nathan, F., & Paz-Ares, L.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- From Memorial Sloan Kettering Cancer Center Hospital, New York (M.D.H.); Prof. Dr. Ion Chiricuta Institute of Oncology and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.); Centrum Onkologii–Instytut im. Marii Sklodowskiej-Curie, Warsaw, Poland (A.P.); Seoul National University Bundang Hospital, Seoul, South Korea (J.S.L.); Ohio State University, Columbus (G.A.O.); Hôpital Sainte Musse, Toulon, France (C.A.-V.); Ospedale Santa Maria della Misericordia, Perugia,...
- Fox Chase Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-31
- Volume
- 378
- Issue
- 22
- Pages
- 2093-2104
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7193684
- OpenAlex
- W2797675588
- Cited by
- 3,063
- References
- 22
- Citations by year
- 2026: 100 · 2025: 184 · 2024: 222 · 2023: 289 · 2022: 419 · 2021: 499 · 2020: 559 · 2019: 542 · 2018: 247
- FWCI
- 174.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb, Inc.
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- nivolumab, ipilimumab, non-small cell lung cancer, tumor mutational burden, PD-L1 expression, immune checkpoint inhibitors, progression-free survival, chemotherapy comparison, stage IV lung cancer, treatment-related adverse events, treatment response biomarkers, objective response rate, immunotherapy biomarkers, safety and tolerability
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Biomarkers, Tumor, Disease-Free Survival, Kaplan-Meier Estimate, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
